Amanda Tey

Clayton, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury.

Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury.

Journal: The Journal of antimicrobial chemotherapy

Published: August 12, 2025

Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice.

Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice.

Journal: EClinicalMedicine

Published: December 11, 2024

Survivorship clinic attendance improves completion but not timeliness of cardiac surveillance post anthracyclines.

Survivorship clinic attendance improves completion but not timeliness of cardiac surveillance post anthracyclines.

Journal: Cardio-oncology (London, England)

Published: September 12, 2024

Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach.

Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach.

Journal: Internal medicine journal

Published: August 22, 2024

Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.

Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.

Journal: EJHaem

Published: May 09, 2024

High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma.

High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma.

Journal: European journal of haematology

Published: November 20, 2022

Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.

Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.

Journal: European journal of haematology

Published: February 03, 2021

Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.

Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.

Journal: Leukemia & lymphoma

Published: September 28, 2020

Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.

Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.

Journal: Annals of hematology

Published: April 22, 2020

Showing 1-9 of 9

Last Updated: 09/26/2026